Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Painenz is a combination analgesic and antipyretic medication primarily composed of paracetamol (acetaminophen) and caffeine. Paracetamol exerts its therapeutic effects by inhibiting prostaglandin synthesis in the central nervous system, which provides relief from mild to moderate pain and reduces fever. Caffeine acts as an analgesic adjuvant by antagonizing adenosine receptors, which not only enhances the analgesic efficacy of paracetamol but also increases its rate of absorption and provides mild vasoconstrictive properties that are particularly beneficial for treating headaches and migraines. Developed and manufactured by Emzor Pharmaceuticals, Painenz is widely utilized for the symptomatic relief of various conditions, including headaches, muscle aches, menstrual cramps, and toothaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Painenz.